Efficacy and clinical application of HIV/AIDS tablets

Biktarvy is a drug composed of Bictegravir (Bictegravir), emtricitabine (Emtricitabine), and Tenofovir alafenamide (TAF) The fixed combination preparation consisting of three ingredients is considered to be one of the most widely used single-pill combination drugs in the current antiretroviral treatment of HIV (AIDS). Its design concept is to complete a complete and highly effective treatment plan through one daily dose, reducing patients' medication burden and compliance issues. Compared with traditional regimens that require a combination of multiple drugs, Bituvi's simplified model improves the convenience and quality of life of long-term HIV management.

In terms of mechanism of action, bictegravir in Bituvir is a type of integrase inhibitor that can block the integration of HIV virus genes into the genome of human T lymphocytes and curb viral replication from the source; emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors that form a double barrier by interfering with the reverse transcription link necessary in the virus replication process. This multi-pathway blocking method greatly improves the persistence of viral suppression and resistance barriers, and also reduces treatment failures due to drug resistance.

In clinical application, Bituvi is mainly used for treatment-naïve patients with HIV-1 infection and some patients who are changing regimens. Overseas guidelines recommend it as a first-line treatment option because of its high resistance barrier, relatively mild side effects, and good kidney and bone safety. Especially for patients who require long-term medication, Bituvir has shown advantages in reducing the nephrotoxicity and bone density loss associated with traditional tenofovir.

It not only emphasizes virological suppression, but also focuses on overall patient health management, covering compliance, long-term safety and comorbidity management. For Chinese patients, Bituvi is gradually being incorporated into clinical practice by more experts. Its once-a-day, three-drug-in-one feature significantly improves the convenience of treatment and contributes to long-term control for a wider range of people.

Reference materials:https://www.biktarvy.com/